白蛋白结合型紫杉醇在晚期恶性肿瘤患者中的应用和疗效观察

Application and Effect of Albumin-bound Paclitaxel in Patients with Advanced Malignant Tumor

目的探讨白蛋白结合型紫杉醇在晚期恶性肿瘤患者中的应用效果与安全性。方法选择2018年1月-2019年9月该院收治的22例晚期恶性肿瘤患者为研究对象,接受白蛋白结合型紫杉醇单药与联合治疗患者分别为12例、10例。分析治疗近期疗效和不良反应。结果22例患者中完全缓解(CR)为1例,部分缓解(PR)为8例,稳定(SD)为9例,进展(PD)为4例,RR为40.91%(9/22),DCR为81.82%(18/22),而单药治疗组RR为33.33%(4/12),DCR为75.00%(9/12);联合治疗组中RR为50.00%(5/10),DCR为90.00%(9/10);22例患者中治疗相关不良反应多为Ⅰ级、Ⅱ级,其中主要不良反应为骨髓抑制40.91%(9/22),其次为白细胞减少31.82%(7/22)、血红蛋白减少27.27%(6/22)、乏力27.27%(6/22)。结论白蛋白结合型紫杉醇单药或联合方案治疗晚期恶性肿瘤效果较好,疾病控制率高,治疗耐受性好,值得临床推广。

Objective To investigate the application effect and safety of albumin-bound paclitaxel in patients with advanced malignant tumors.Methods 22 patients with advanced malignant tumors treated in the hospital from January2018 to September 2019 were selected as the research subjects.12 patients received albumin-bound paclitaxel monotherapy and 10 patients combination therapy,respectively.Analyze the short-term efficacy and adverse effects of treatment.Results Among the 22 patients,1 cases was complete response(CR),8 cases were partial response(PR),9 cases were stable(SD),4 cases were progressive(PD),and RR was 40.91%(9/22).DCR was 81.82%(18/22),while the RR in the monotherapy group was 33.33%(4/12),the DCR was 75.00%(9/12);the RR in the combination treatment group was 50.00%(5/10),and DCR 90.00%(9/10);treatment-related adverse reactions were mostly gradeⅠandⅡin22 patients,the main adverse reaction was bone marrow suppression of 40.91%(9/22),followed by 31.82%(7/22),Hemoglobin decreased by 27.27%(6/22),fatigue was 27.27%(6/22).Conclusion The albumin-bound paclitaxel monotherapy or combined regimen has good effect on advanced malignant tumors,high disease control rate,good treatment tolerance,and is worth clinical promotion.